Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
This study is investigating a new medication, lenacapavir, for individuals living with HIV-1 infection. It's specifically for those whose current HIV treatments are no longer working effectively due to the virus becoming resistant to multiple medicines. The main goal is to find out if adding lenacapavir to their existing treatment for a short period can help lower the amount of HIV in their body. Researchers will also look at how safe the new drug is and how well it works over a longer time when combined with other effective HIV medicines. This is an important step towards finding new options for people with complex HIV-1 infection.
A colpo d'occhio
Risultati
Risultati di questo studio
Pubblicato October 2021I risultati di questo studio sono stati pubblicati.
Di cosa tratta questo studio?
This study is looking at a new medicine called lenacapavir, designed for people living with HIV-1. HIV, or human immunodeficiency virus, is a condition that affects your immune system. While there are many effective treatments for HIV, some people find that over time, the virus changes and becomes resistant to the medicines they are taking. This means their current treatments might stop working as well as they used to.
The study aims to help people who are in this situation – those whose HIV has become resistant to several different types of medication. The researchers want to see if adding lenacapavir to their current treatment can help reduce the amount of HIV in their body. This process will happen in two main stages: first, they'll check how well lenacapavir works on its own for a short time, and then they'll see how it performs when combined with other effective HIV medicines.
Finding new treatment options is really important for people with multi-drug resistant HIV, as it can be challenging to manage their condition. This study hopes to provide data that could eventually lead to new ways to help people keep their HIV under control and improve their overall health.
Punti chiave
- This study is for people with HIV-1 whose current treatments are not fully effective.
- It tests a new medicine, lenacapavir, for multi-drug resistant HIV.
- Participation involves taking new medicine (pills and injections) and regular doctor visits.
- You might receive a placebo initially, but everyone eventually receives the new drug.
- The study aims to find new ways to treat complex HIV infections.
Chi può essere idoneo?
To join this study, you would generally need to be at least 18 years old. In some parts of the world, like North America, teenagers aged 12 and above who weigh at least 35 kg might also be able to join. You need to have been on an HIV treatment for more than 8 weeks that isn't currently working well for you, meaning your blood test shows a certain level of HIV in your body.
Additionally, your HIV must show signs of resistance to several different types of existing HIV medications. This means your doctors would confirm that your HIV is difficult to treat with many standard drugs. You should also not have an ongoing Hepatitis C infection at the time of screening.
Your doctor will be able to check all these details to see if you meet the full requirements for taking part in this study.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Are you aged 18 or over (or 12-17 and at least 35kg in some regions)?
- Is your current HIV medicine not fully controlling your virus?
- Has your doctor told you your HIV is resistant to several different treatments?
- Do you not have an active Hepatitis C infection?
- Are you able and willing to take new medicines as directed?
- Could you attend regular hospital visits for check-ups and tests?
Cosa comporta la partecipazione?
If you join this study, you might receive either the new medicine, lenacapavir, or a dummy pill (placebo) for a short period, in addition to your current HIV treatment. After this initial stage, all participants will receive lenacapavir along with a new combination of HIV medicines chosen by your doctors that are expected to work well for you. This will involve taking pills by mouth and also receiving some injections under the skin. You'll have regular hospital visits, blood tests, and check-ups to monitor your health, how the medicine is affecting your HIV, and to look for any side effects. The total duration of your involvement in the study will be explained in detail by the study team.
Rischi e benefici potenziali
Località (75)
- Ruane Clinical Research Group IncCodice postale verificatoLos Angeles, Stati Uniti
- Mills Clinical ResearchCodice postale verificatoLos Angeles, Stati Uniti
- Eisenhower Health Center at RimrockCodice postale verificatoPalm Springs, United States
- One Community HealthCodice postale verificatoSacramento, Stati Uniti
- Yale University; School of MedicineCodice postale verificatoNew Haven, Stati Uniti
- Washington Health InstituteCodice postale verificatoWashington D.C., Stati Uniti
- Midland Florida Clinical Research Center, LLCCodice postale verificatoDeLand, United States
- Gary J. Richmond, M.D., P.A.Codice postale verificatoFort Lauderdale, United States
- Midway Immunology and Research CenterCodice postale verificatoFt. Pierce, United States
- Floridian Clinical ResearchCodice postale verificatoHialeah, United States
- AIDS Healthcare Foundation - South BeachCodice postale verificatoMiami Beach, Stati Uniti
- Orlando Immunology CenterCodice postale verificatoOrlando, Stati Uniti
Domande comuni
What is multidrug resistance (MDR) in HIV?
Multidrug resistance means that the HIV in your body has changed and become resistant to several different types of HIV medicines, making your current treatments less effective.
What is an 'Optimized Background Regimen' (OBR)?
An OBR is a new combination of existing HIV medicines chosen by your doctor that are expected to work well for you, even if your HIV has some resistance.
Will I know if I'm getting the active drug or a placebo?
Initially, it's possible you might get a placebo, and you won't know which one you're receiving. However, after a short period, all participants will receive the active study medicine, lenacapavir.
How is lenacapavir given?
Lenacapavir will be given as a tablet you take by mouth and also as an injection under your skin.
Can I stop taking part in the study at any time?
Yes, your participation is completely voluntary, and you can decide to stop taking part at any time without it affecting your future medical care.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.